Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck KGaA Rebounds After COVID-19 Lockdowns

Mavenclad And Fertility Business Back On Track

Sep 17 2020

• By Kevin Grogan

Euro_Notes_500 — Merck Sticking To €2bn pharma sales target by 2022 • Source: Shutterstock

Related Content

Merck KGaA Keen To Remain Key Player In MS Now And In Future

May 14 2019

GSK Makes I-O Move With Merck KGaA Deal Worth Up To €3.7bn

Feb 05 2019

Merck KGaA Fertility Business And Mavenclad Held Back By COVID-19 But Recovery Signs

Aug 07 2020

Merck KGaA Tightens Focus With Allergopharma Sale

Feb 20 2020

Related Companies

Merck KGaA

Dermapharm AG

GSK plc

Pfizer Inc.

Additional Topics

Sales & Earnings Business Strategies Coronavirus COVID-19 Commercial Immune Disorders BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window